Junshi Biosciences Announces FDAs Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
India Ratings Affirms Star Health Insurance Company’s Rating at ‘IND AA+’ with a Stable Outlook
CHENNAI, India, Oct. 1, 2025 /PRNewswire/ -- Star Health and Allied Insurance…
